SelectION Overview
- Status
-
Private
- Employees
-
3
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$5.43M
- Investors
-
7
SelectION General Information
Description
Developer of peptide therapeutics designed to assist in the treatment of autoimmune diseases and disorders. The company's therapeutics use an ion channel technology platform to discover and develop selective peptides by functionally inhibiting and eliminating disease-associated chronically activated TEM cells without compromising the protective immune response, enabling healthcare professionals to achieve effective treatments for pain management and oncology.
Contact Information
Website
www.selectiontherapeutics.comCorporate Office
- 655 India Street
- Suite 204
- San Diego, CA 92101
- United States
Corporate Office
- 655 India Street
- Suite 204
- San Diego, CA 92101
- United States
SelectION Timeline
SelectION Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC | 15-Sep-2025 | $5.43M | Completed | Clinical Trials - Phase 1 | ||
| 7. Later Stage VC (Series B) | 05-Jun-2023 | Completed | Clinical Trials - Phase 1 | |||
| 6. Later Stage VC (Series A1) | 08-Apr-2021 | Completed | Clinical Trials - Phase 1 | |||
| 5. Later Stage VC (Series A) | 30-May-2019 | Completed | Clinical Trials - Phase 1 | |||
| 4. Grant | 23-Jan-2013 | Completed | Clinical Trials - Phase 1 | |||
| 3. Grant | 16-Jul-2012 | Completed | Clinical Trials - Phase 1 | |||
| 2. Seed Round | 15-Mar-2002 | Completed | Clinical Trials - Phase 1 | |||
| 1. Accelerator/Incubator | 01-Jan-2001 | Completed | Clinical Trials - Phase 1 |
SelectION Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A-1 | ||||||||
| Series A | 16,354,270 | $0.000010 | 8% | $0.25 | $0.25 | 1x | $0.25 | 48.49% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
SelectION Patents
SelectION Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026093602-A1 | D-cys38 epimer of kv1.3 inhibitor | Pending | 04-Nov-2024 | ||
| WO-2026093599-A1 | Method for peptide oxidation and folding | Pending | 04-Nov-2024 | ||
| WO-2026093598-A1 | Peptide with low content of d-cys38 epimer | Pending | 04-Nov-2024 | ||
| AU-2024408749-A1 | Peptide for treating atopic dermatitis | Pending | 21-Dec-2023 | ||
| EP-4827891-A1 | Peptide for treating atopic dermatitis | Pending | 21-Dec-2023 | A61K38/16 |
SelectION Signals
SelectION Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Global Source Ventures | Venture Capital | Minority | ||
| Mey Capital Matrix | Venture Capital | Minority | ||
| SDL Ventures | Venture Capital | Minority | ||
| Bay Area Biosciences Association | Corporation | |||
| Bundesministerium für Bildung und Forschung | Government |
SelectION FAQs
-
Where is SelectION headquartered?
SelectION is headquartered in San Diego, CA.
-
What is the size of SelectION?
SelectION has 3 total employees.
-
What industry is SelectION in?
SelectION’s primary industry is Drug Discovery.
-
Is SelectION a private or public company?
SelectION is a Private company.
-
What is SelectION’s current revenue?
The current revenue for SelectION is .
-
How much funding has SelectION raised over time?
SelectION has raised $19.6M.
-
Who are SelectION’s investors?
Global Source Ventures, Mey Capital Matrix, SDL Ventures, Bay Area Biosciences Association, and Bundesministerium für Bildung und Forschung are 5 of 7 investors who have invested in SelectION.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process